A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis

Inclusion Criteria:

- Are ambulatory.

- Have an established diagnosis of radiographic axial spondyloarthritis (rad-xSpA) with
sacroiliitis defined radiographically according to the modified New York criteria.

- Participants have a history of back pain ≥3 months with age at onset <45 years.

- Have had prior treatment with at least 1 and not more than 2 TNF inhibitors.

- Must have had an inadequate response to 2 or more NSAIDs at the therapeutic dose range
for a total duration of at least 4 weeks OR have a history of intolerance to NSAIDs.

- Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.

Exclusion Criteria:

- Have total ankylosis of the spine.

- Have never taken a TNF inhibitor medication or have taken more than 2.

- Have recently received a live vaccine within 12 weeks or have had a vaccination with
Bacillus Calmette-Guerin (BCG) within the past year.

- Have an ongoing or serious infection within the last 12 weeks or evidence of active
tuberculosis.

- Have a compromised immune system.

- Have any other serious and/or uncontrolled diseases.

- Have either a current diagnosis or a recent history of malignant disease.

- Have had major surgery within 8 weeks of baseline, or will require surgery during the
study.

- Are pregnant or breastfeeding.